Patents by Inventor Bo-Jeng WANG

Bo-Jeng WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in alzheimer's disease
    Patent number: 10576082
    Abstract: Use of an ErbB2 inhibitor for promoting ErbB2-regulated autophagic degradation or clearance of APP-C99 and APP intracellular domain (AICD) and/or alleviating production of Abeta 40 and Abeta 42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an ErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof.
    Type: Grant
    Filed: September 3, 2017
    Date of Patent: March 3, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Yung-Feng Liao, Bo-Jeng Wang
  • ErbB2 REGULATES AUTOPHAGIC FLUX TO MODULATE THE PROTEOSTASIS OF APP-CTFs IN ALZHEIMER'S DISEASE
    Publication number: 20190209565
    Abstract: Use of an ErbB2 inhibitor for promoting ErbB2-regulated autophagic degradation or clearance of APP-C99 and APP intracellular domain (AICD) and/or alleviating production of Abeta 40 and Abeta 42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an ErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof.
    Type: Application
    Filed: September 3, 2017
    Publication date: July 11, 2019
    Applicant: Academia Sinica
    Inventors: Yung-Feng LIAO, Bo-Jeng WANG